XML 20 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 30, 2018
Mar. 31, 2017
Statement of Cash Flows [Abstract]    
Net income $ 115,857 $ 16,700
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 371 281
Stock-based compensation expense 9,305 4,713
Amortization of debt discounts and debt issuance costs 0 89
Interest paid in kind 0 2,068
Gain on other equity investments (209) 0
Other 1,722 680
Changes in assets and liabilities:    
Trade and other receivables (10,755) 6,541
Inventory, net (906) 34
Unbilled collaboration revenue (38,014) 0
Prepaid expenses and other current assets 1,900 (881)
Other long-term assets (346) (19)
Accounts payable (183) (1,916)
Accrued compensation and benefits (317) (5,844)
Accrued clinical trial liabilities (4,498) 347
Accrued collaboration liabilities (1,000) 0
Deferred revenue (2,652) 35,139
Other current and long-term liabilities 1,533 10,926
Net cash provided by operating activities 71,808 68,858
Cash flows from investing activities:    
Purchases of property and equipment (2,947) (804)
Purchases of investments (116,537) (124,494)
Proceeds from maturities of investments 87,504 122,507
Proceeds from sale of investments 6,238 37,294
Proceeds from other equity investments 209 0
Net cash provided by (used in) investing activities (25,533) 34,503
Cash flows from financing activities:    
Repayment of convertible notes and term loan payable 0 (80,000)
Proceeds from exercise of stock options 1,875 9,675
Taxes paid related to net share settlement of equity awards (2,129) (1,543)
Net cash used in financing activities (254) (71,868)
Net increase in cash, cash equivalents and restricted cash 46,021 31,493
Cash, cash equivalents and restricted cash at beginning of period 188,314 155,836
Cash, cash equivalents and restricted cash at end of period $ 234,335 $ 187,329